



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 Issue: IV Month of publication: April 2025

DOI: <https://doi.org/10.22214/ijraset.2025.68764>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Artificial Intelligence in Clinical Trials

Mr. Chaitanya Sunil Kalbhor¹, Rekha Kolape², Rushikesh Madane³, Shrikant Shendge⁴, Nitin Gawai⁵
B.Pharmacy Department Mahadev Kanchan College of Pharmaceutical Education and Research, Uruli Kanchan Pune
Maharashtra India

Abstract: *By improving the effectiveness, precision, and flexibility of clinical research procedures, artificial intelligence (AI) is quickly changing the clinical trial environment. AI provides creative answers to many of the conventional problems encountered in clinical trials, ranging from intelligent patient recruiting and protocol design to real-time data analysis and safety monitoring. Improved patient matching, quicker decision-making, and better trial results have all been made possible by recent developments in machine learning, natural language processing, and predictive analytics. Personalized treatment plans, decentralized trial models, and quicker drug development are all possible with the use of AI technology into clinical trials as they advance further. The main uses, current developments, and anticipated future developments of AI in clinical trials are highlighted in this paper, highlighting the technology's potential to transform clinical research and enhance patient care.*

Keywords: *Artificial Intelligence, Clinical Trials, Machine Learning, Predictive Analytics, Patient Recruitment, Adaptive Trial Design, Real-World Data, Natural Language Processing, Digital Health, Drug Development.*

I. INTRODUCTION

Clinical trials are structured research studies conducted on humans to evaluate the safety, efficacy, and best practices of new or existing drugs, medical devices, or treatments. They play a vital role in translating lab discoveries into real-world medical applications, ensuring that therapies meet ethical and scientific standards¹⁻².

The primary goal of clinical trials is to generate reliable data on the benefits and risks of medical interventions, ultimately improving patient care. The concept dates back to James Lind's scurvy study in 1747 and has since evolved with strict ethical regulations, particularly after historical abuses like the Tuskegee Syphilis Study³.

Today, trials follow international standards such as Good Clinical Practice (GCP) under the guidance of regulatory authorities like the FDA, EMA, and CDSCO. Clinical trials are conducted in four phases, starting with safety testing (Phase I) and ending with post-marketing surveillance (Phase IV)⁴.

Modern trials are increasingly complex, integrating genetic data, AI, and real-world evidence. The COVID-19 pandemic highlighted the value of adaptive trial designs and global collaboration⁵.

This study aims to explore the types, methodologies, ethics, challenges, and advancements in clinical trials, providing insights for researchers, healthcare professionals, and policymakers working toward safer and more effective healthcare⁶.

II. OBJECTIVE OF THE REVIEW

Assessing the safety, effectiveness, and tolerability of novel or current medical therapies in people is the main goal of clinical trials. The purpose of these studies is to collect high-quality, empirically supported data to aid in clinical judgement and regulatory approval.

1) Efficacy Evaluation

Determines whether the treatment provides the intended therapeutic benefit under controlled conditions.

2) Dose Optimization

Identifies the most effective and safest dose through dose-ranging studies.

3) Pharmacokinetics & Drug Interactions

Studies how the drug is absorbed, metabolized, and excreted, and its biological effects.

4) Comparative Effectiveness

Compares new treatments to placebos or standard therapies to assess outcomes and safety.

5) Long-Term Safety Monitoring

Tracks delayed or rare side effects, especially during post-marketing (Phase IV) studies.

6) Clinical Guideline Development

Provides evidence for updating medical guidelines and standard practices.

7) *Regulatory Approval*

Supplies essential data for drug approval by regulatory agencies like FDA, EMA, and CDSCO⁷⁻¹⁰.

III. TYPES OF CLINICAL TRIALS

Clinical trials can be generally categorized according to their interventional nature, design, and purpose. Choosing the best approach to answer a particular research topic requires an understanding of the many kinds of clinical trials. Each kind has unique uses in medical research as well as advantages and disadvantages.

1) *Interventional Trial*

Participants are actively assigned treatments to test their effects. Used to establish cause-effect relationships.

2) *Observational Trials*

No interventions; researchers observe outcomes naturally. Includes cohort, case-control, and cross-sectional studies.

3) *Randomized Controlled Trials (RCTs)*

Participants are randomly assigned to groups. Considered the gold standard for minimizing bias.

4) *Open-Label Trials*

Both researchers and participants know the treatment being given. Useful when blinding isn't possible.

5) *Blinded Trials (Single, Double, Triple)*

Reduces bias by keeping group assignments hidden from participants, researchers, or data analysts.

6) *Crossover Trials*

Participants receive multiple treatments in sequence, acting as their own controls. Suitable for chronic conditions.

7) *Pilot & Feasibility Studies*

Small-scale trials to test the practicality and design of a larger, full-scale trial.

8) *Adaptive Trials*

Allow changes in trial protocol (like dosage or sample size) based on interim results. Efficient for dynamic conditions.

9) *Equivalence & Non-Inferiority Trials*

check if a new treatment is equal to or not worse than an existing one. Common for biosimilar drug studies.

10) *Phase IV (Post-Marketing) Trials*

Monitor a drug's long-term safety and effectiveness after approval. Detect rare or delayed side effects¹¹⁻²⁰.

IV. PHASES OF CLINICAL TRIALS

Clinical trials are generally conducted in four sequential phases (Phase 0–IV), each with specific objectives and increasing complexity. These phases ensure a comprehensive evaluation of a drug or intervention before and after it reaches the market.

1) *Micro dosing Studies (Exploratory Trials) Phase 0*

the goal is to do a preliminary analysis of human pharmacokinetics and pharmacodynamics.

Participants: Very few (10–15 individuals in good health).

Design: Less than 1% of the dosage required to have a pharmacologic effect is given at sub-therapeutic doses.

Result: Assists in establishing if a medication acts in people in a manner consistent with preclinical research.

Relevance: Saves time and money before moving on to more extensive testing.

2) *Phase I:*

Dose determination and safety

Goal: Assess a novel drug's pharmacokinetics, safety, and tolerability.

20–100 healthy volunteers or occasionally patients (particularly in cancer) make up the participants.

Design:

either single-blind or open-label.

The maximum tolerated dosage (MTD) is ascertained through dose-escalation experiments.

Result: Identification of metabolism, excretion profiles, safe dose range, and adverse effects.

3) *Phase II:*

Profiling of Efficacy and Side Effects

Goal: Determine the drug's effectiveness and further assess its safety.

Participants: 100–300 individuals suffering from the intended illness.

Design: Frequently controlled and randomized.

Includes research on dose-response.

Result: Determines the short-term adverse effect profile and therapeutic dosage. Establishes if the medication has therapeutic value or biological action.

4) *Confirmatory Trials, Phase III*

Goals: Verify the medication's effectiveness, track adverse effects, and contrast with conventional therapies.

1,000–3,000+ patients from various centers participated.

Design: Double-blind, controlled, and randomized (RCT).

Multinational, multicenter trials.

Result: The information gathered is submitted to and approved by regulatory bodies. Guarantees the authenticity of statistics.

5) *Phase IV:*

Monitoring After Marketing

Goal: After the medicine is approved, track its long-term safety, efficacy, and uncommon side effects.

Participants: People in general.

Design: either interventional or observational.

May entail examinations of actual evidence.

Result: identifies drug-drug interactions, uncommon or delayed adverse events, and directs label changes.²¹⁻²⁵

V. DESIGN AND METHODOLOGY

Proper design and methodology are crucial for generating reliable, reproducible, and ethically sound results in clinical trials. A well-structured trial reduces bias, ensures participant safety, and strengthens scientific credibility.

The definition of a trial protocol design is a comprehensive plan that describes the goals, design, technique, statistical considerations, and operational elements of the trial.

Contains:

1) *Study justification*

Criteria for inclusion and removal

Comparators and interventions

Measures of results

Moral considerations

2) *Using randomization*

Goal: Balances confounding factors and removes selection bias.

Types:

Basic Randomization: Similar to tossing a coin.

Block randomization guarantees that each group has an equal number of members.

Using stratified randomization, groupings (such as age and gender) are balanced.

3) *Masking, or blinding*

Participants alone are not aware of their group in a single-blind study.

Double-blind: No one knows, not even the volunteers or the researchers.

Triple-blind: The data analyzer, researcher, and participant are all blindfolded.

Relevance: Reduces bias in detection and performance.

4) *Groups of Control*

Comparison with an inert agent is known as placebo control.

Active-Controlled: Evaluation vs conventional treatment.

Particularly in non-pharmacological studies, no treatment or usual care control.

5) *Calculating the Sample Size*

Significance: To identify statistically significant changes, sufficient power is required.

Factors include power ($1-\beta$), variability, significance level (α), and effect size.

Tools: Statistical programs such as SAS, nQuery, or G*Power.

6) *Measures of Outcome*

The main variable addressing the trial's goal is called the primary outcome (e.g., survival rate, symptom reduction).

7) *Secondary Outcomes*: Additional effects (e.g., quality of life, side effects)

Endpoints may be composite, surrogate (biomarkers), or clinical (mortality).

8) *Plan for Statistical Analysis (SAP)*

a predetermined strategy for examining trial results.

Contains: Techniques for dealing with missing data

Analysis of subgroups

Per-protocol (PP) versus intention-to-treat (ITT) analysis

9) *Observation and Evaluation*

Information Committees for Monitoring (DMCs): Examine current safety statistics.

Analyses data at predetermined times using interim analysis.

Inspections and Audits: Verify adherence to legal and GCP requirements.²⁶⁻³⁰

VI. ETHICAL CONSIDERATIONS

Ethical integrity is the backbone of clinical research. Clinical trials must respect the rights, dignity, and safety of participants.

Ethical considerations are enforced by international declarations, guidelines, and oversight bodies.

1) *Knowledgeable Consent*

The trial's goal, potential dangers, and advantages must all be adequately disclosed to participants.

Participation is entirely voluntary, and withdrawal is possible at any moment.

Prior to involvement, consent must be acquired, recorded in writing, and described in a clear and concise manner.

2) *Institutional Review Board (IRB) or Ethics Committee*

An independent ethical body, or IRB, must examine and approve each clinical experiment.

Their responsibility is to:

Examine the consent forms and research procedure.

Protect the rights and safety of participants.

Keep an eye on the trial's conduct

3) *Evaluation of Risk-Benefit*

Participants should be at little risk during trials.

The possible advantage (to the individual or to society) must be greater than the danger.

It is crucial to continuously check any negative consequences.

4) *Confidentiality & Privacy*

Confidentiality of participant data is required.

Coded IDs are used in place of private data.

Compliance with data protection laws such as HIPAA (USA) or GDPR (Europe).

5) *Populations at Risk*

Enrolment is handled with extra care:

Kids

Women who are pregnant

Senior Citizens

Groups that are economically or educationally disadvantaged

6) *Declarations and Ethical Guidelines*

The WMA, or Declaration of Helsinki, is the gold standard for research ethics.

Guidelines for ICH-GCP: centered on ethical and scientific excellence.

The USA's Belmont Report: focusses on justice, beneficence, and respect.

There is more ethical monitoring.³¹⁻³²

VII.REGULATORY FRAMEWORK

Clinical trials are regulated to ensure compliance, safety, and scientific integrity. Each country or region has its own regulatory agencies and submission requirements

1) *International Regulatory Authorities*

2) *Key Regulatory Documents*

- Investigational New Drug (IND) Application: Required to begin human trials (USA).
- Clinical Trial Application (CTA): Submitted to national authority before trial initiation.
- New Drug Application (NDA) or Marketing Authorization Application (MAA): Submitted after successful Phase III trials.

3) *Good Clinical Practice (GCP)*

- Harmonized set of ethical and scientific standards.
- Ensures:
- Protection of human rights
- Accurate trial data
- Responsibilities of sponsors, investigators, and monitors.³³⁻³⁵

VIII. CHALLENGES IN CLINICAL TRIALS

1) *Recruitment and Retention*

- Slow enrollment due to strict eligibility criteria.
- Dropouts due to side effects, long study durations, or loss of motivation.

2) *High Costs*

- Clinical trials are expensive:
- Multi-center studies
- Regulatory compliance
- Data management
- Small companies often struggle with funding.

3) *Globalization and Regulatory Heterogeneity*

- Variability in regulations between countries causes delays.
- Harmonization remains a challenge for multinational trials.

4) *Ethical Dilemmas*

- Balancing risk vs. benefit in terminal illnesses.
- Use of placebos when effective treatment exists.
- Consent challenges in low-literacy populations.

5) *Data Integrity Issues*

- Incomplete or inaccurate data collection.

- Risk of fraud, bias, or selective reporting.
 - Need for robust monitoring systems.
- 6) *Long Duration*
- Trials can take 5–10 years from conception to approval.
 - Regulatory reviews and data analysis further extend timelines.³⁶⁻³⁷

IX. RECENT TRENDS IN AI FOR CLINICAL TRIALS

- 1) *AI-Driven Patient Recruitment and Matching*
- AI algorithms scan EHRs and health databases to identify eligible patients.
 - Reduces recruitment time and increases patient diversity.
 - Example: IBM Watson Health is used to match cancer patients with clinical trials based on genomic profiles.
- 2) *Natural Language Processing (NLP)*
- Extracts meaningful insights from unstructured data like clinical notes, case reports, and publications.
 - Automates data entry and improves protocol feasibility assessment.
- 3) *Predictive Analytics*
- AI predicts trial outcomes, patient dropout risks, and adverse events using historical data.
 - Helps in risk mitigation and better trial planning.
- 4) *Adaptive Trial Design*
- AI supports real-time modifications to trial parameters (e.g., dosage, sample size) based on ongoing results.
 - Makes trials more flexible and responsive.
- 5) *Wearable and Remote Monitoring Integration*
- AI processes data from wearable devices to monitor patient vitals and symptoms continuously.
 - Enables Decentralized Clinical Trials (DCTs) with real-time feedback and safety monitoring.
- 6) *Fraud Detection and Data Validation*
- AI algorithms flag inconsistent or fabricated data, ensuring data integrity.
 - Supports regulatory compliance and ethical conduct.³⁸⁻⁴⁰

X. FUTURE PERSPECTIVES

- 1) *Personalized and Precision Trials*
- Integration of AI with genomics and biomarkers to create highly individualized treatment trials.
 - Expected to improve response rates and reduce trial failures.
- 2) *Automated Protocol Generation*
- AI will assist in designing trial protocols based on disease trends, historical data, and real-world evidence.
 - Will drastically reduce setup time.
- 3) *Fully Virtual Trials*
- Combining AI with telemedicine and mobile health apps could allow clinical trials to be conducted entirely online.
 - Increases accessibility for patients in remote areas.
- 4) *AI-Augmented Regulatory Submissions*
- AI tools will help in organizing and validating regulatory documents, streamlining the approval process.

- Speeds up time to market for new drugs.

5) *Real-Time Data Analytics and Decision Support*

- Continuous data analysis through AI can guide immediate clinical decisions during trials.
- Reduces adverse effects and enhances patient safety.

6) *AI-Powered Synthetic Control Arms*

- AI can generate synthetic control groups using historical data, reducing the need for placebo groups and improving ethical standards.⁴¹⁻⁴²

XI. CONCLUSION

By introducing speed, economy, and precision, artificial intelligence is completely changing the clinical trial ecology. AI is changing every step of the trial process, from real-time analytics and adaptable trial designs to intelligent patient recruiting and data monitoring. The advantages of AI are indisputable, despite the fact that ethical, legal, and data protection issues continue to be major obstacles. Clinical trials will become more patient-centric, cost-effective, and data-driven in the future as technology advances and becomes more integrated with healthcare infrastructure. Adopting AI is essential for modernizing clinical research and spurring medical innovation, not merely a choice.

REFERENCES

- [1] Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44–56.
- [2] Esteva, A., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25(1), 24–29.
- [3] Weng, C., et al. (2020). Artificial intelligence for clinical trial design. *Trends in Pharmacological Sciences*, 41(12), 1050–1061.
- [4] Shivade, C., et al. (2014). A review of approaches to identifying patient phenotype cohorts using electronic health records. *Journal of the American Medical Informatics Association*, 21(2), 221–230.
- [5] Sarker, I. H. (2021). Machine learning: Algorithms, real-world applications and research directions. *SN Computer Science*, 2, 160.
- [6] Liu, Y., et al. (2020). Artificial intelligence in clinical trials: a review. *Trends in Pharmacological Sciences*, 41(12), 882–891.
- [7] Mak, K. K., et al. (2019). Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*, 24(3), 773–780.
- [8] Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA*, 319(13), 1317–1318.
- [9] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine*, 380(14), 1347–1358.
- [10] Dinerstein, S. (2021). Artificial Intelligence (AI) and the Future of Clinical Trials. *Clinical Trials Arena*.
- [11] Xie, J., et al. (2020). Deep learning for natural language processing in electronic health records: a systematic review. *JAMIA*, 27(3), 457–470.
- [12] Sorousmeh, S. M. R., & Najarian, K. (2021). Artificial intelligence in clinical decision support systems. *Computers in Biology and Medicine*, 127, 104104.
- [13] Chan, A. W., et al. (2013). Increasing value and reducing waste: addressing inaccessible research. *The Lancet*, 383(9913), 257–266.
- [14] Wang, Y., et al. (2019). The role of AI in drug discovery and development. *Drug Discovery Today*, 24(4), 1066–1075.
- [15] Kommrusch, R., et al. (2021). Machine learning for clinical trial prediction: a systematic review. *Journal of Biomedical Informatics*, 113, 103639.
- [16] Ghassemi, M., et al. (2018). Opportunities in machine learning for healthcare. *arXiv preprint, arXiv:1806.00388*.
- [17] Hernandez-Boussard, T., et al. (2020). Predicting patient outcomes using AI. *Annual Review of Public Health*, 41, 505–516.
- [18] Wang, F., et al. (2018). Clinical risk prediction with machine learning: a guide for clinicians. *BMJ*, 361, k1494.
- [19] Zarinn, D. A., et al. (2017). Update on trial registration 11 years after the ICMJE policy was established. *New England Journal of Medicine*, 376(4), 383–391.
- [20] Wenzel, M., et al. (2021). Improving patient selection in clinical trials using AI. *Artificial Intelligence in Medicine*, 118, 102112.
- [21] Yim, J., et al. (2020). Predicting conversion to wet age-related macular degeneration using deep learning. *Nature Medicine*, 26(6), 892–899.
- [22] Bhattacharya, S., et al. (2022). AI and real-world evidence in clinical trial design. *Frontiers in Pharmacology*, 13, 832348.
- [23] Barda, N., et al. (2021). Developing a COVID-19 risk prediction model using machine learning. *Nature Medicine*, 27(3), 568–576.
- [24] Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature Biomedical Engineering*, 2(10), 719–731.
- [25] Goecks, J., et al. (2020). How machine learning will transform biomedicine. *Cell*, 181(1), 92–101.
- [26] Subramanian, J., & Simon, R. (2010). Overfitting in prediction models—Is it a problem only in high dimensions? *Contemporary Clinical Trials*, 31(6), 588–595.
- [27] Luo, Y., et al. (2016). Natural language processing for EHR-based phenotyping: a systematic review. *Journal of the American Medical Informatics Association*, 23(1), 212–220.
- [28] Zame, W. R., et al. (2020). Machine learning in healthcare: a critical review. *Nature Medicine*, 26(4), 389–400.
- [29] Shah, N. H., et al. (2019). Artificial intelligence and clinical trials: the promise and the challenges. *American Journal of Managed Care*, 25(3), 123–126.
- [30] London, A. J. (2019). Artificial intelligence and black-box medical decisions: accuracy versus explainability. *Hastings Center Report*, 49(1), 15–21.
- [31] Topol, E. J. (2020). The convergence of human and artificial intelligence: implications for clinical trials. *Nature Reviews Drug Discovery*, 19(5), 279–280.
- [32] Jiang, F., et al. (2017). Artificial intelligence in healthcare: past, present and future. *Stroke and Vascular Neurology*, 2(4), 230–243.
- [33] Miotto, R., et al. (2018). Deep learning for healthcare: review, opportunities and challenges. *Briefings in Bioinformatics*, 19(6), 1236–1246.
- [34] Andreu-Perez, J., et al. (2015). Big data for health. *IEEE Journal of Biomedical and Health Informatics*, 19(4), 1193–1208.
- [35] Roberts, M., et al. (2021). Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19. *Nature Machine Intelligence*, 3(3), 199–217.



- [36] Brennan, P. F., et al. (2021). Using AI for adaptive clinical trials: benefits, risks, and challenges. *Clinical Trials*, 18(4), 391–400.
- [37] Norori, N., et al. (2021). Addressing bias in AI in health care: a new frontier. *Nature Medicine*, 27(12), 2061–2063.
- [38] Perakslis, E. D. (2020). Digital health and clinical trials: AI-based recruitment. *NPJ Digital Medicine*, 3(1), 1–3.
- [39] Rieke, N., et al. (2020). The future of privacy-preserving AI in clinical research. *Nature Machine Intelligence*, 2(6), 341–343.
- [40] Banerjee, I., et al. (2020). Reading race: AI recognises patient racial identity in medical imaging. *The Lancet Digital Health*, 4(2), e79–e90.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)